FRAZIER HEALTHCARE PARTNERS

Alpine Immune Sciences Announces $91 Million Private Placement

Retrieved on: 
Wednesday, September 15, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Nasdaq, Securities and Exchange Commission (Nigeria), Security (finance), Forward-looking statement, Securities Exchange Act of 1934, ALPN, Frazier Healthcare Partners, Securities Act of 1933, Private Securities Litigation Reform Act, APRIL, LinkedIn, Pembrolizumab, NASDAQ, BAFF, Twitter, Philosophy, Nature, SEC, Protein engineering, Sale, Cancer, Lupus, Exercise, Pharmaceutical industry, Alpine Immune Sciences, Inc., Frazier Healthcare Partners, ALPINE IMMUNE SCIENCES, INC., FRAZIER HEALTHCARE PARTNERS

Pursuant to the terms of the securities purchase agreement, at the closing of the private placement, Alpine will issue approximately 6.5 million shares of common stock and approximately 3.2 million prefunded warrants to purchase the same number of shares of common stock.

Key Points: 
  • Pursuant to the terms of the securities purchase agreement, at the closing of the private placement, Alpine will issue approximately 6.5 million shares of common stock and approximately 3.2 million prefunded warrants to purchase the same number of shares of common stock.
  • Additional details regarding the private placement will be included in a Form 8-K to be filed by Alpine with the Securities and Exchange Commission (SEC).
  • Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics.
  • The Alpine logo is a registered trademark or trademark of Alpine Immune Sciences, Inc. in various jurisdictions.

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate

Retrieved on: 
Thursday, July 29, 2021
Research, Medical Supplies, Infectious diseases, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Medical specialties, Clinical medicine, Health care, Norovirus, Vomiting, Takeda Pharmaceutical Company, Takeda, Gastroenteritis, Vaccine, Takeda Pharmaceutical Company Limited, Frazier Healthcare Partners, HilleVax, TAKEDA PHARMACEUTICAL COMPANY LIMITED, FRAZIER HEALTHCARE PARTNERS, HILLEVAX

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialize Takedas norovirus vaccine candidate.

Key Points: 
  • Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialize Takedas norovirus vaccine candidate.
  • Takeda will retain commercialization rights in Japan and HilleVax will integrate certain Japan development activities into its global development.
  • Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies.
  • Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

EPTAM Precision and Mendell Join Forces to Better Serve Ortho, Cardio, RAS, and MIS Customers

Retrieved on: 
Wednesday, May 19, 2021
Other Manufacturing, Medical devices, Surgery, Engineering, Cardiology, Manufacturing, Other Health, Physical therapy, General Health, Health, Mendell, Anodizing, Physical sciences, Chemistry, Natural sciences, EPTAM, Mendell, Frazier Healthcare Partners, EPTAM, MENDELL, FRAZIER HEALTHCARE PARTNERS

b'EPTAM Precision Solutions (\xe2\x80\x9cEPTAM\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d), a Frazier Healthcare Partners (\xe2\x80\x9cFrazier\xe2\x80\x9d) portfolio company, is pleased to announce the acquisition of Mendell Machine and Manufacturing (\xe2\x80\x9cMendell\xe2\x80\x9d).

Key Points: 
  • b'EPTAM Precision Solutions (\xe2\x80\x9cEPTAM\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d), a Frazier Healthcare Partners (\xe2\x80\x9cFrazier\xe2\x80\x9d) portfolio company, is pleased to announce the acquisition of Mendell Machine and Manufacturing (\xe2\x80\x9cMendell\xe2\x80\x9d).
  • Mendell is a medical component manufacturer located in Lakeville, MN that specializes in precision CNC micro-machining of implantable devices for the orthopedic, structural heart, cardiovascular, and endovascular markets.
  • For the cardiovascular and endovascular markets, Mendell manufactures products such as micro-cutters, micro-housings, and other micro-surgical components.
  • In addition to these small scale, high-precision manufacturing capabilities, Mendell offers in-house finishing operations including laser marking, passivation, and anodizing, amongst others.